Xtant Medical Holdings (XTNT) Cost of Revenue (2010 - 2025)

Xtant Medical Holdings (XTNT) has reported Cost of Revenue for 16 consecutive years, with $11.3 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Cost of Revenue fell 3.16% year-over-year to $11.3 million in Q3 2025; TTM through Sep 2025 was $50.5 million, a 13.49% increase from a year earlier, with the FY2024 full-year figure at $49.1 million, up 36.88% from the prior year.
• Cost of Revenue was $11.3 million for Q3 2025 at Xtant Medical Holdings, up from $11.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $15.5 million in Q4 2024 and troughed at $4.5 million in Q1 2021.
• A 5-year average of $8.9 million and a median of $7.8 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue dropped 13.82% in 2021 and jumped 57.54% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $6.3 million in 2021, then rose by 10.98% to $7.0 million in 2022, then jumped by 57.54% to $11.0 million in 2023, then soared by 41.18% to $15.5 million in 2024, then declined by 27.28% to $11.3 million in 2025.
• The last three Cost of Revenue figures came in at $11.3 million (Q3 2025), $11.1 million (Q2 2025), and $12.7 million (Q1 2025), per Business Quant data.